Anika’s Monovisc is a single-injection viscosupplement therapy approved in the European economic area for treatment of osteoarthritis symptoms in all synovial joints. Other viscosupplements are indicated for specific joints, and may require up to five injections for the same treatment.
Charles Sherwood, president and CEO of Anika, said: “Monovisc is designed for faster pain relief and longer durability thanks to its proprietary cross-linking technology. Monovisc’s single-injection regimen benefits both patients and physicians by minimizing the number of office visits, thereby lowering costs to the patient and the healthcare system.”